Whereas PIK3CA mutations and HER2 amplification have been identified in the majority of preclinical breast cancer studies as determinant of sensitivity to PI3K pathway inhibition downstream of RTKs, the correlation between PTEN deficiency and response is less clear. Here, PIK3CA is linked to breast carcinoma.